UBS raises IDEXX Laboratories stock price target on strong international growth
UBS raised its price target on IDEXX Laboratories (IDXX) to $700, citing strong international growth and a beat-and-raise quarter. The company reported 11.87% revenue growth and a 62.72% gross margin. Despite a 20% stock surge, UBS maintains a Neutral rating, noting potential overvaluation.
How this was made
The 30-second read
Why it matters
The upgrade could attract new buying interest and sustain the recent 20% price gain.
Market read
Earnings beat and analyst upgrade provide fresh bullish catalyst for IDXX.
What to watch
Potential pricing pressure from a looming price war in the companion animal market.
Background
IDXX reported Q3 results that beat expectations, prompting UBS to raise its price target.
Ticker impact
UBS raised IDXX price target to $700 after the company posted Q3 earnings beat (EPS $3.96, revenue $1.21B) and 20% share jump.
upward pressure as the market prices in the higher target and earnings beat.
The price‑target increase reflects fresh bullish expectations; earnings beat confirms earnings momentum.
Market effects
Strong performance may lift the veterinary diagnostics sector.
U.S. consumer discretionary sentiment reinforced.
Limited to U.S. and sector investors.
Counterpoint
The high P/E of 47 may suggest overvaluation despite the upgrade.
Key entities
- analystUBS
Raised price target to $700, maintaining Neutral rating.



